ADReCS

Pharmaceutical Information

Drug Name	Hydroxyurea
Drug ID	BADD_D01110
Description	An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.
Indications and Usage	For management of melanoma, resistant chronic myelocytic leukemia, and recurrent, metastatic, or inoperable carcinoma of the ovary and Sickle-cell anemia.
Marketing Status	approved
ATC Code	L01XX05
DrugBank ID	DB01005
KEGG ID	D00341
MeSH ID	D006918
PubChem ID	3657
TTD Drug ID	D07CWD
NDC Product Code	0904-6939; 35369-0006; 49452-3650; 55154-7143; 61269-403; 68084-284; 70518-3615; 51927-0072; 0555-0882; 55154-3554; 69315-164; 38779-1354; 42291-321; 71770-105; 49884-724; 17337-0023; 0003-6335; 0003-6337; 60429-265; 61269-835; 70518-0916; 55512-0003; 61269-402; 71770-120; 0003-0830; 51552-0851; 62049-135; 0003-6336; 61269-404; 10135-702; 71052-323; 17337-0022
UNII	X6Q56QN5QC
Synonyms	Hydroxyurea \| Hydroxycarbamid \| Oncocarbide \| Hydrea

Chemical Information

Molecular Formula	CH4N2O2
CAS Registry Number	127-07-1
SMILES	C(=O)(N)NO
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Skin lesion	23.03.03.010	0.000112%		-
Skin necrosis	23.03.03.011	0.000224%		-
Skin ulcer	23.07.03.003; 24.04.03.007	0.002295%
Somnolence	17.02.04.006; 19.02.05.003	-	-
Speech disorder	17.02.08.003; 19.19.02.002; 22.12.03.027	0.000168%		-
Spermatogenesis abnormal	21.03.03.002	0.000336%		-
Spleen disorder	01.09.02.003	0.000112%		-
Splenic infarction	01.09.02.004; 24.04.08.024	0.000168%		-
Splenomegaly	01.09.02.001	0.001869%		-
Squamous cell carcinoma	16.16.01.002	0.001343%		-
Squamous cell carcinoma of skin	16.03.02.005; 23.08.02.005	0.001119%		-
Stillbirth	08.04.01.006; 18.01.02.002	0.000112%		-
Stomatitis	07.05.06.005	0.000660%
Subarachnoid haemorrhage	12.01.10.011; 17.08.01.010; 24.07.04.004	0.000112%		-
Systemic lupus erythematosus	10.04.03.004; 15.06.02.003; 23.03.02.006	-	-	-
Tenderness	08.01.08.005	-	-	-
Testicular disorder	21.13.01.002	0.000112%
Therapeutic response decreased	08.06.01.016	0.000280%		-
Thrombocytopenia	01.08.01.002	0.002183%		-
Thrombocytosis	01.08.02.001	0.000470%		-
Tongue neoplasm malignant stage unspecified	07.21.07.003; 16.13.07.003	0.000504%		-
Tumour lysis syndrome	14.05.01.004; 16.32.03.002	0.000448%
Ulcer	08.03.06.001	0.000548%		-
Upper gastrointestinal haemorrhage	07.12.02.006; 24.07.02.024	0.000168%
Ureteric obstruction	20.06.01.005	-	-	-
Urinary incontinence	17.05.01.008; 20.02.02.010	0.000112%
Uterine cancer	16.12.05.001; 21.07.02.003	0.000168%		-
Vasculitis	10.02.02.006; 24.12.04.027	0.000168%
Ventricular tachycardia	02.03.04.010	0.000112%
Vomiting	07.01.07.003	-	-

The 9th Page First Pre 9 10 11 12 13 Next Last Total 13 Pages